Physician profile
Adam Gulhan
NPI 1841294345
$1,201.11
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $61.23 · 2022: $207 · 2023: $257 · 2024: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $475.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $335.91 | 2019-2023 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $258.20 | 2019-2022 | |
| Abbvie INC. | $202.22 | 2023-2024 | |
| Ucb, INC. | $98.17 | 2019-2024 | Briviact, Nayzilam |
| Biogen, INC. | $48.00 | 2019-2020 | |
| Genzyme Corporation | $46.90 | 2019 | |
| Celgene Corporation | $29.16 | 2022-2023 | Zeposia |
| Genentech USA, INC. | $26.77 | 2024 | Ocrevus |
| Sumitomo Pharma America, INC. | $26.17 | 2023-2024 | Aptiom |
| Kyowa Kirin, INC. | $24.23 | 2024 | Nourianz |
| Grifols USA, LLC | $19.20 | 2024 | Gamunex-C |
| Acadia Pharmaceuticals INC | $18.98 | 2024 | Nuplazid |
| Neurocrine Biosciences, INC. | $18.95 | 2023 | Ingrezza |
| Eisai INC. | $16.42 | 2023 | |
| Lilly USA, LLC | $16.34 | 2024 | Amyvid |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $15.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Gulhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.